These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes. Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313 [TBL] [Abstract][Full Text] [Related]
4. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Nagata T; Fukuzawa T; Takeda M; Fukazawa M; Mori T; Nihei T; Honda K; Suzuki Y; Kawabe Y Br J Pharmacol; 2013 Oct; 170(3):519-31. PubMed ID: 23751087 [TBL] [Abstract][Full Text] [Related]
5. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748 [TBL] [Abstract][Full Text] [Related]
6. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. Abdel-Wahab AF; Bamagous GA; Al-Harizy RM; ElSawy NA; Shahzad N; Ibrahim IA; Ghamdi SSA Biomed Pharmacother; 2018 Jul; 103():59-66. PubMed ID: 29635129 [TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats. Oraby MA; El-Yamany MF; Safar MM; Assaf N; Ghoneim HA Biomed Pharmacother; 2019 Jan; 109():910-920. PubMed ID: 30551545 [TBL] [Abstract][Full Text] [Related]
8. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. Birnbaum Y; Bajaj M; Yang HC; Ye Y Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169 [TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Tang L; Wu Y; Tian M; Sjöström CD; Johansson U; Peng XR; Smith DM; Huang Y Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E563-E576. PubMed ID: 28811292 [TBL] [Abstract][Full Text] [Related]
10. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition? Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease. Østergaard MV; Secher T; Christensen M; Salinas CG; Roostalu U; Skytte JL; Rune I; Hansen HH; Jelsing J; Vrang N; Fink LN Am J Physiol Renal Physiol; 2021 Aug; 321(2):F149-F161. PubMed ID: 34180715 [TBL] [Abstract][Full Text] [Related]
12. SGLT2 Inhibitors and the Diabetic Kidney. Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829 [TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524 [TBL] [Abstract][Full Text] [Related]
14. An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy. Bai Z; Xie T; Liu T; Chen Z; Yu L; Zhang C; Luo J; Chen L; Zhao X; Xiao Y Front Endocrinol (Lausanne); 2022; 13():967822. PubMed ID: 36213291 [TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. Lee DM; Battson ML; Jarrell DK; Hou S; Ecton KE; Weir TL; Gentile CL Cardiovasc Diabetol; 2018 Apr; 17(1):62. PubMed ID: 29703207 [TBL] [Abstract][Full Text] [Related]
17. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269 [TBL] [Abstract][Full Text] [Related]
18. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study). Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298 [TBL] [Abstract][Full Text] [Related]
19. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells. Maki T; Maeno S; Maeda Y; Yamato M; Sonoda N; Ogawa Y; Wakisaka M; Inoguchi T Sci Rep; 2019 Mar; 9(1):4703. PubMed ID: 30886225 [TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice. Cha JJ; Park HJ; Yoo JA; Ghee J; Cha DR; Kang YS Kidney Blood Press Res; 2024; 49(1):81-90. PubMed ID: 38185119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]